

**ASX RELEASE**

**28 February 2023**

### **ACCENT Trial Recruitment Progress**

#### **HIGHLIGHTS:**

- Enrolment of the second cohort of patients in the ongoing Phase 1b/2a ACCENT clinical trial is now complete.
- Dose escalation in subsequent cohorts will be subject to the review of clinical data by the Safety Committee.

**Melbourne, Australia:** Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce completion of enrolment of the second cohort of patients in the ongoing Phase 1b/2a ACCENT clinical trial in frontline patients with pancreatic cancer.

The first stage of the ACCENT trial is designed to test ascending doses of AMP945 given in combination with standard gemcitabine/nab-paclitaxel chemotherapy in patients with advanced pancreatic cancer. After 1 month of treatment, the trial’s Safety Committee will review the clinical data collected and, subject to the data, authorise dose escalation of AMP945 in a subsequent cohort.

Amplia’s CEO and Managing Director Dr Chris Burns commented: “We continue to make good progress in the ACCENT trial having recruited the three patients for Cohort 2 within one month of opening enrolment for this cohort. We are extremely grateful to the patients and their loved ones, as well as the clinical trial sites in Melbourne, Sydney and Brisbane, for helping us progress this dose-escalation phase of the trial so efficiently.”

#### **About the ACCENT Trial**

The protocol for the ACCENT trial is entitled “A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients”.

The trial is to be conducted in two stages. The first, Phase 1b stage of the trial, is a single-arm open-label study to select an optimal dose of AMP945 by assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AMP945 when dosed in combination with gemcitabine and nab-paclitaxel (Abraxane®) in first-line patients with advanced pancreatic cancer.

The second, Phase 2a, stage of the trial is also a single-arm open-label study and is designed to perform an assessment of the optimal dose of AMP945 in combination with gemcitabine and nab-paclitaxel. The primary endpoint of the Phase 2a trial is the Objective Response Rate (ORR) of patients to treatment. Further endpoints will assess efficacy by other means as well as safety and tolerability.

More information about the ACCENT trial, including a list of participating sites, can be found via our website and at ClinicalTrials.gov under the identifier [NCT05355298](https://clinicaltrials.gov/ct2/show/study/NCT05355298). The Company will provide further updates on the trial as recruitment proceeds.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

**Investor Contact:**

Dr Chris Burns  
Chief Executive Officer  
[chris@ampliatx.com](mailto:chris@ampliatx.com)

**Media Contact:**

HACK Director, Haley Chartres  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 423 139 163

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit [www.ampliatx.com](http://www.ampliatx.com) and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/ampliatx).